Rein Therapeutics Inc (RNTX) Income Statement
RNTX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsRNTX revenue and net income
RNTX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RNTX quarterly EPS vs estimates
Rein Therapeutics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 13, 2026 (estimate $-0.10).
RNTX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1,000 | $63,000 | — | — | — | — |
| Gross profit | −$1,000 | −$63,000 | — | — | — | — |
| Research & development | $11.0M | $14.2M | $3,991 | $17,967 | $17,008 | $11,166 |
| Sales, general & admin | $10.9M | $27.7M | $11,357 | $9,680 | $9,597 | $9,330 |
| Total operating expenses | $21.9M | $65.1M | $16,276 | $27,647 | $26,605 | $20,496 |
| Operating income | −$21.9M | −$65.1M | −$16,276 | −$27,647 | −$26,605 | −$20,496 |
| Interest income | — | $400,000 | $400,000 | $300,000 | — | — |
| Income before taxes | −$50.6M | −$64.3M | −$15,732 | −$27,329 | −$26,164 | −$21,157 |
| Income taxes | −$712,000 | −$1.5M | — | — | — | — |
| Net income | −$49.9M | −$62.9M | −$15,732 | −$27,329 | −$26,164 | −$21,157 |
| EBITDA | −$50.6M | −$28.0M | $103,652 | $141,671 | −$26,043 | −$20,333 |
| EPS (diluted) | −$1.96 | −$1.84 | −$3.38 | −$6.00 | −$4.28 | −$10.32 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | $1,000 | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | −$1,000 | — | — | — | — | — | — | — |
| Research & development | $3.6M | $3.1M | $2.0M | $1.7M | $4.3M | $3.1M | $3.3M | $3.7M | $3,741 | $3,463 | $1,972 | $22 |
| Sales, general & admin | $2.4M | $2.2M | $2.0M | $3.8M | $2.6M | $2.6M | $4.9M | $2.3M | $5,298 | $3,742 | $5,330 | $1,955 |
| Total operating expenses | $6.1M | $5.2M | $4.0M | $5.5M | $6.9M | $5.6M | $42.8M | $6.1M | $9,039 | $7,205 | $7,290 | $1,983 |
| Operating income | −$6.1M | −$5.2M | −$4.0M | −$5.5M | −$6.9M | −$5.6M | −$42.8M | −$6.1M | −$9,039 | −$7,205 | −$7,290 | −$1,983 |
| Interest income | — | — | — | — | — | — | — | — | — | — | $78,000 | $155,000 |
| Income before taxes | −$6.4M | −$5.8M | −$32.7M | −$5.6M | −$6.8M | −$5.5M | −$42.4M | −$5.8M | −$8,942 | −$7,113 | −$7,339 | −$1,827 |
| Income taxes | — | — | −$712,000 | — | — | −$1.5M | $1,544 | — | — | — | — | — |
| Net income | −$6.4M | −$5.8M | −$32.0M | −$5.6M | −$6.8M | −$5.5M | −$41.0M | −$5.8M | −$8,942 | −$7,113 | −$7,339 | −$1,827 |
| EBITDA | −$6.4M | −$5.2M | −$3.9M | −$5.6M | −$6.8M | −$5.5M | −$5,797 | −$5.8M | −$8,938 | −$7,054 | −$7,250 | −$1,965 |
| EPS (diluted) | −$0.10 | −$0.19 | −$1.22 | −$0.21 | −$0.28 | −$0.25 | −$0.26 | −$0.27 | −$0.45 | −$0.86 | −$1.54 | −$0.40 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RNTX's financial statements (latest annual report filed March 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RNTX financial results
Rein Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $49.9 million. Diluted earnings per share came to −$1.96.
See the RNTX stock overview for the latest quote and news, or the RNTX chart for price history and technical indicators.
RNTX income statement FAQ
Does Rein Therapeutics have revenue?
Rein Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Rein Therapeutics profitable?
No. Rein Therapeutics reported a net loss of $49.9 million in fiscal 2025.
How much does Rein Therapeutics spend on research and development?
Rein Therapeutics spent $11.0 million on research and development in fiscal 2025.
What are Rein Therapeutics's earnings per share?
Rein Therapeutics earned $-1.96 per diluted share in fiscal 2025, compared with $-1.84 a year earlier.
When will Rein Therapeutics report its next earnings?
Rein Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Rein Therapeutics's fiscal year end?
Rein Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 26, 2026.